Citations

Clear

16281 citation(s) found for "Yu, David".

Association of Pre-pandemic High Attenuation Areas on Lung CT and COVID-19 Hospitalization and Death: The C4R Study
Kim, J. , Balte, P., Sun, Yifei , Smith, B.M. , Podolanczuk, A., Lee, J.S., Washko, G.R., Hunninghake, G.M., Regan, E.A., Woodruff, P., Ortega, Victor E. , Lynch, David A. , Laine, Andrew F. , Hoffman, E.A., Oelsner, E., Hermann, E.A. , Schwartz, David A. , Stukovsky, Karen Hinckley , Make, Barry J. , Hoffman, E.A., Barr, R. Graham

Mayo Clinic

C107. MICROBIAL RESPIRATORY INFECTIONS DISCOVERIES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6814-A6814

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6814 Get It

Efficacy and Safety of Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis With Lung Involvement: A Post Hoc Analysis of the ADVOCATE Trial
Fussner, Lynn A. , Bray, Sarah , Gurlin, Rachel E , Group, ADVOCATE Study, Specks, Ulrich , Jayne, David , Merkel, Peter A.

Mayo Clinic

A26. IMPROVING OUTCOMES IN SARCOIDOSIS, RARE LUNG DISEASE AND LUNG TRANSPLANT | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1182-A1182

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1182 Get It

Developing a Machine Learning Algorithm That Analyzes Voice Patterns to Identify Risk of Aspiration
Abdalla, Abdelmohaymin , Charney, Sara , Holyfield, Stacy , Brown, Alexandra R. , Higgins, Matthew , Ortega, Victor E. , Varghese, C., Zhang, J., Brown, A., Higgins, M., Liss, Julie , Zhang, Nan , Lott, David G. , Berisha, Visar

Mayo Clinic

A13. TOWARDS IMPLEMENTATION: NEW BIOMARKERS IN ILD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1004-A1004

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1004 Get It

Alternative Pathway Complement Activation and Low Circulating Inhibitors Associate With Severity and Mortality in COVID-19 and Non-COVID Sepsis
Meyer, N.J., Devalaraja‐Narashimha, Kishor , Ehmann, Peter, Afolayan, Sunday, DerOhannessian, Stephanie, Spade, G., Ittner, C.A.G., Turner, A.P., Esperanza, Mika, Dunn, Thomas, Weaver, JoEllen , Biobank, P. PennMedicine, Zhu, Olivia, Scott, Daniel A. , Hamon, Sara , Wistermayer, A., Hersch, L., Burczynski, Michael E., Hamilton, Jennifer D. , Jones, T.K., Shashaty, M.G.S. , Reilly, J.P., Laudański, Krzysztof , Ko, Jina , Scott, D., Hooper, Andrea T. , Glass, David J. , Giannini, Heather M. , Morton, L., FitzGerald, Garret A , Rader, Daniel J

Mayo Clinic

A103. DYSREGULATED PATHWAYS IN SEPSIS AND LUNG INJURY: SEARCHING FOR TREATABLE TRAITS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2830-A2830

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2830 Get It

Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, Ronald , Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard N. , McLaughlin, Vallerie V. , Vachiéry, Jean‐Luc , Zamanian, R.T., Cravets, Matt , Roscigno, R.F., Mottola, David, Parsley, E., Aranda, R., Zisman, Lawrence S. , Investigators, on behalf of the TORREY Study, Sitbon, Olivier , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B., Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Ghofrani, Hossein Ardeschir

Mayo Clinic

A14. BUILDING LEGO(LAND): LESSONS LEARNED FROM LARGE SCALE CLINICAL TRIALS IN PAH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1011-A1011

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1011 Get It

Characterization of Perioperative Serotonin in Patients Undergoing Orthotopic Liver Transplantation
Zott, Tobias , Kersten, Isabelle, Ortner, Max, Hüpper, Maria Noelle, Berlakovich, Gabriela , Silberhumer, Gerd R. , Berlakovich, Gabriela A , Silberhumer, Gerd R , Pereyra, David , Starlinger, Patrick

Mayo Clinic

Journal of Clinical Medicine | April 30, 2024 | Volume: 13 | Issue: 9 | Pages: 2640

10.3390/jcm13092640 | PMID 38731169 Get It

Background: Platelets were shown to be relevant for liver regeneration. In particular, platelet-stored serotonin (5-HT) proved to be a pro-regenerative factor in this process. The present study aimed to investigate the perioperative course of 5-HT and evaluate associations with patient and graft outcomes after othotopic liver transplantation (OLT). Methods: 5-HT was quantified in plasma and serum of 44 OLT recipients perioperatively, and in their respective donors. Olthoff’s criteria for early allograft dysfunction (EAD) were used to evaluate postoperative outcomes. Results: Patients with higher donor intra-platelet 5-HT per platelet (IP 5-HT PP) values had significantly lower postoperative transaminases (ASAT POD1: p = 0.006, ASAT POD5: p = 0.006, ASAT POD10: p = 0.02, ALAT POD1: p = 0.034, ALAT POD5: p = 0.017, ALAT POD10: p = 0.04). No significant differences were seen between postoperative 5-HT values and the occurrence of EAD. A tendency was measured that donor IP 5-HT PP is lower in donor-recipient pairs that developed EAD (p = 0.07). Conclusions: Donor IP 5-HT PP might be linked to the postoperative development of EAD after OLT, as higher donor levels are correlated with a more favorable postoperative course of transaminases. Further studies with larger cohorts are needed to validate these findings.
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Mezzanotte-Sharpe, Jessica , O’Neill, Anne, Arteaga, Carlos L. , Yang, Ximing J. , Cella, David , Meropol, Neal J. , Alpaugh, R. Katherine , Saphner, Thomas J. , Swaney, Robert E., Hoelzer, Karen L., Gradishar, William J. , Sundaram, P. Kothai, Jilani, Shamim Z., Perez, Edith A. , Jahanzeb, Mohammad , Reid, Sonya , Mayer, Ingrid A. , Wagner, Lynne I. , Abramson, Vandana G. , Lin, Nancy U. , Wolff, Antonio C. , Sledge, George W.

Mayo Clinic

No container title available | April 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4295044/v1 | PMID 38746356 Get It

Abstract Background In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical and preliminary clinical activity of the trastuzumab and bevacizumab combination, ECOG-ACRIN E1105 trial was developed to determine if the addition of bevacizumab to a chemotherapy and trastuzumab combination for first-line therapy would improve progression-free survival (PFS) in patients with HER2-positive MBC. Findings: 96 patients were randomized to receive standard first-line chemotherapy and trastuzumab with or without bevacizumab between November 2007 and October 2009, and 93 began protocol therapy. Induction therapy was given for 24 weeks, followed by maintenance trastuzumab with or without bevacizumab. 60% (56/93) began carboplatin and 74% (69/93) completed 6 cycles of induction therapy. Primary endpoint was PFS. Median PFS was 11.1 and 13.8 months for placebo and bevacizumab arms, respectively (hazard ratio [HR] 95%, Confidence Interval [Cl] for bevacizumab vs. placebo: 0.73 [0.43–1.23], p = 0.24), and at a median follow-up of 70.7 months, median survival was 49.1 and 63 months (HR [95% Cl] for OS: 1.09 [0.61–1.97], p = 0.75). The most common toxicities across both arms were neutropenia and hypertension, with left ventricular systolic dysfunction, fatigue, and sensory neuropathy reported more frequently with bevacizumab. Conclusions In this trial, the addition of bevacizumab did not improve outcomes in patients with metastatic HER2-positive breast cancer. Although the trial was underpowered due to smaller than anticipated sample size, these findings corroborated other clinical trials during this time.
Validation of the Learner Engagement Instrument for Continuing Professional Development
Cook, David A. , Stephenson, Christopher R.

Mayo Clinic

Academic Medicine | April 29, 2024 | Volume: 99 | Issue: 9 | Pages: 1024-1031

10.1097/acm.0000000000005749 | PMID 38683885 Get It

Abstract Purpose Learner engagement is the energy learners exert to remain focused and motivated to learn. The Learner Engagement Instrument (LEI) was developed to measure learner engagement in a short continuing professional development (CPD) activity. The authors validated LEI scores using validity evidence of internal structure and relationships with other variables. Method Participants attended 1 of 4 CPD courses (1 in-person, 2 online livestreamed, and 1 either in-person or livestreamed) in 2018, 2020, 2021, and 2022. Confirmatory factor analysis was used to examine model fit for several alternative structural models, separately for each course. The authors also conducted a generalizability study to estimate score reliability. Associations were evaluated between LEI scores and Continuing Medical Education Teaching Effectiveness (CMETE) scores and participant demographics. Statistical methods accounted for repeated measures by participants. Results Four hundred fifteen unique participants attended 203 different CPD presentations and completed the LEI 11,567 times. The originally hypothesized 4-domain model of learner engagement (domains: emotional, behavioral, cognitive in-class, cognitive out-of-class) demonstrated best model fit in all 4 courses, with comparative fit index ≥ 0.99, standardized root mean square residual ≤ 0.031, and root mean square error of approximation ≤ 0.047. The reliability for overall scores and domain scores were all acceptable (50-rater G-coefficient ≥ 0.74) except for the cognitive in-class domain (50-rater G-coefficient of 0.55 to 0.66). Findings were similar for both in-person and online delivery modalities. Correlation of LEI scores with teaching effectiveness was confirmed (rho=0.58), and a small correlation was found with participant age (rho=0.19); other associations were small and not statistically significant. Using these findings, we generated a shortened 4-item instrument, the LEI Short Form. Conclusions This study confirms a 4-domain model of learner engagement and provides validity evidence that supports using LEI scores to measure learner engagement in both in-person and livestreamed CPD activities.